Exro Technologies Inc. (TSX:EXRO)
Canada · Delayed Price · Currency is CAD 0.0800
+0.0050 (6.67%)
Aug 1, 2025, 3:59 PM EDT
CTI BioPharma Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 27.43 | 23.07 | - | 2.19 | - | - | Upgrade | |
Cost of Revenue | 38.28 | 31.72 | - | 1.9 | - | - | Upgrade |
Gross Profit | -10.85 | -8.64 | - | 0.28 | - | - | Upgrade |
Selling, General & Admin | 44.19 | 42.64 | 25.71 | 24.91 | 12.74 | 6.02 | Upgrade |
Research & Development | 6.97 | 8.92 | 11.79 | 8.77 | 7.41 | 2.27 | Upgrade |
Operating Expenses | 91.19 | 84.21 | 44.16 | 38.52 | 30.64 | 10.71 | Upgrade |
Operating Income | -102.04 | -92.85 | -44.16 | -38.24 | -30.64 | -10.71 | Upgrade |
Interest Expense | -11.54 | -8.46 | -2.33 | -0.86 | -0.12 | - | Upgrade |
Interest & Investment Income | - | - | - | - | - | 0.03 | Upgrade |
Currency Exchange Gain (Loss) | -1.04 | -1.33 | -0.97 | 1.78 | -0.03 | -0.22 | Upgrade |
Other Non Operating Income (Expenses) | 19 | 19.5 | -1.26 | 0.07 | -0.02 | 0 | Upgrade |
EBT Excluding Unusual Items | -95.61 | -83.14 | -48.72 | -37.26 | -30.8 | -10.9 | Upgrade |
Merger & Restructuring Charges | -2.52 | -4.59 | - | - | - | - | Upgrade |
Impairment of Goodwill | -153.18 | -153.18 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -0.67 | -1.57 | -2.2 | -2.7 | 6.22 | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.15 | 0.01 | 0.22 | -0.07 | - | -0.1 | Upgrade |
Asset Writedown | -70.03 | -70.03 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.03 | Upgrade |
Pretax Income | -323.17 | -312.51 | -50.71 | -40.02 | -24.58 | -10.97 | Upgrade |
Income Tax Expense | -24.94 | -24.94 | - | - | - | - | Upgrade |
Earnings From Continuing Operations | -298.22 | -287.57 | -50.71 | -40.02 | -24.58 | -10.97 | Upgrade |
Earnings From Discontinued Operations | -1.38 | -1.37 | 0.09 | - | - | - | Upgrade |
Net Income | -299.61 | -288.93 | -50.62 | -40.02 | -24.58 | -10.97 | Upgrade |
Net Income to Common | -299.61 | -288.93 | -50.62 | -40.02 | -24.58 | -10.97 | Upgrade |
Shares Outstanding (Basic) | 552 | 444 | 162 | 138 | 120 | 90 | Upgrade |
Shares Outstanding (Diluted) | 552 | 444 | 162 | 138 | 120 | 90 | Upgrade |
Shares Change (YoY) | 230.87% | 174.65% | 17.45% | 14.61% | 33.01% | 44.60% | Upgrade |
EPS (Basic) | -0.54 | -0.65 | -0.31 | -0.29 | -0.20 | -0.12 | Upgrade |
EPS (Diluted) | -0.54 | -0.65 | -0.31 | -0.29 | -0.20 | -0.12 | Upgrade |
Free Cash Flow | -60.88 | -53.45 | -51.44 | -41.57 | -30.31 | -8.21 | Upgrade |
Free Cash Flow Per Share | -0.11 | -0.12 | -0.32 | -0.30 | -0.25 | -0.09 | Upgrade |
Gross Margin | -39.57% | -37.45% | - | 13.03% | - | - | Upgrade |
Operating Margin | -372.03% | -402.42% | - | -1749.63% | - | - | Upgrade |
Profit Margin | -1092.38% | -1252.20% | - | -1831.43% | - | - | Upgrade |
Free Cash Flow Margin | -221.99% | -231.64% | - | -1902.32% | - | - | Upgrade |
EBITDA | -70.17 | -62.64 | -41.28 | -36.9 | -30.29 | -10.62 | Upgrade |
EBITDA Margin | -255.84% | -271.48% | - | - | - | - | Upgrade |
D&A For EBITDA | 31.87 | 30.21 | 2.88 | 1.34 | 0.35 | 0.08 | Upgrade |
EBIT | -102.04 | -92.85 | -44.16 | -38.24 | -30.64 | -10.71 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.